Microbial Community Characteristics in Intestinal Mucosal Tissue of Patients With CD

Launched by SHANDONG UNIVERSITY · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the characteristics of bacteria and other microorganisms in the intestines of patients with Crohn's disease (CD). Researchers want to understand how these microbial communities might be linked to the disease and how they could affect treatment outcomes. By analyzing samples from patients, the study aims to fill in important gaps in knowledge about Crohn's disease, which could lead to better understanding and management of the condition.

To participate, individuals must be between 18 and 80 years old and either have Crohn's disease or be healthy individuals undergoing routine colonoscopy. Participants should not have any other digestive or serious health issues, and they should not have taken antibiotics or probiotics within the past week. Those who join the trial will help contribute to important research that could improve care for people with Crohn's disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with Crohn's disease undergoing endoscopic examination
• • Healthy individuals with no symptoms undergoing colonoscopy without any lesions detected
• • Patients undergoing small intestinal endoscopy due to symptoms but with negative examination results.
• • Age between 18 and 80 years.
• • Patients or authorized family members sign the relevant informed consent forms.
• Exclusion Criteria:
• • Patients with concurrent digestive system diseases that may affect the study results, including tumors, infections, or other autoimmune diseases.
• • Patients with concurrent non-digestive system diseases that may affect the study results, including tumors, infections, or autoimmune diseases.
• • Patients who have taken probiotics or antibiotics within the past week.
• • Patients with psychiatric disorders or other conditions that prevent them from cooperating with the study.
• • Patients participating in other clinical trials that may interfere with the results of this study.